98 related articles for article (PubMed ID: 10429649)
1. Human p53-p51 (p53-related) fusion protein: a potent BAX transactivator.
Ikawa S; Obinata M; Ikawa Y
Jpn J Cancer Res; 1999 Jun; 90(6):596-9. PubMed ID: 10429649
[TBL] [Abstract][Full Text] [Related]
2. Cloning and functional analysis of human p51, which structurally and functionally resembles p53.
Osada M; Ohba M; Kawahara C; Ishioka C; Kanamaru R; Katoh I; Ikawa Y; Nimura Y; Nakagawara A; Obinata M; Ikawa S
Nat Med; 1998 Jul; 4(7):839-43. PubMed ID: 9662378
[TBL] [Abstract][Full Text] [Related]
3. Adenovirus-mediated transfer of p53-related genes induces apoptosis of human cancer cells.
Ishida S; Yamashita T; Nakaya U; Tokino T
Jpn J Cancer Res; 2000 Feb; 91(2):174-80. PubMed ID: 10761704
[TBL] [Abstract][Full Text] [Related]
4. The transcriptional activities of p53 and its homologue p51/p63: similarities and differences.
Shimada A; Kato S; Enjo K; Osada M; Ikawa Y; Kohno K; Obinata M; Kanamaru R; Ikawa S; Ishioka C
Cancer Res; 1999 Jun; 59(12):2781-6. PubMed ID: 10383130
[TBL] [Abstract][Full Text] [Related]
5. p51A (TAp63gamma), a p53 homolog, accumulates in response to DNA damage for cell regulation.
Katoh I; Aisaki KI; Kurata SI; Ikawa S; Ikawa Y
Oncogene; 2000 Jun; 19(27):3126-30. PubMed ID: 10871867
[TBL] [Abstract][Full Text] [Related]
6. p53 gene family p51(p63)-encoded, secondary transactivator p51B(TAp63alpha) occurs without forming an immunoprecipitable complex with MDM2, but responds to genotoxic stress by accumulation.
Okada Y; Osada M; Kurata S; Sato S; Aisaki K; Kageyama Y; Kihara K; Ikawa Y; Katoh I
Exp Cell Res; 2002 Jun; 276(2):194-200. PubMed ID: 12027449
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel retrovirus long terminal repeat (LTR) that is targeted by p51A (TAp63gamma) and selective dominant-negative activity of p73L (DeltaNp63alpha) toward p53-responsive promoter activities.
Senoo M; Matsumura Y; Habu S
Biochem Biophys Res Commun; 2001 Aug; 286(3):628-34. PubMed ID: 11511106
[TBL] [Abstract][Full Text] [Related]
8. Analysis of molecular interactions of the p53-family p51(p63) gene products in a yeast two-hybrid system: homotypic and heterotypic interactions and association with p53-regulatory factors.
Kojima T; Ikawa Y; Katoh I
Biochem Biophys Res Commun; 2001 Mar; 281(5):1170-5. PubMed ID: 11243857
[TBL] [Abstract][Full Text] [Related]
9. Selective transcription of p53 target genes by zinc finger-p53 DNA binding domain chimeras.
Falke D; Fisher MH; Juliano RL
Biochim Biophys Acta; 2004 Nov; 1681(1):15-27. PubMed ID: 15566940
[TBL] [Abstract][Full Text] [Related]
10. Distinct promoter elements mediate the co-operative effect of Brn-3a and p53 on the p21 promoter and their antagonism on the Bax promoter.
Perez-Sanchez C; Budhram-Mahadeo VS; Latchman DS
Nucleic Acids Res; 2002 Nov; 30(22):4872-80. PubMed ID: 12433990
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the chemosensitivity of head and neck cancer cells based on the diverse function of mutated-p53.
Shinagawa Y; Kawamata H; Omotehara F; Nakashiro K; Hoque MO; Furihata T; Horiuchi H; Imai Y; Fujimori T; Fujibayashi T
Int J Oncol; 2003 Feb; 22(2):383-9. PubMed ID: 12527938
[TBL] [Abstract][Full Text] [Related]
12. Failure of viral oncoproteins to target the p53-homologue p51A.
Roth J; Dobbelstein M
J Gen Virol; 1999 Dec; 80 ( Pt 12)():3251-3255. PubMed ID: 10567658
[TBL] [Abstract][Full Text] [Related]
13. Induction of apoptosis in melanoma cell lines by p53 and its related proteins.
Yamashita T; Tokino T; Tonoki H; Moriuchi T; Jin HY; Omori F; Jimbow K
J Invest Dermatol; 2001 Oct; 117(4):914-9. PubMed ID: 11676832
[TBL] [Abstract][Full Text] [Related]
14. Induction of apoptosis by the p53-273L (Arg --> Leu) mutant in HSC3 cells without transactivation of p21Waf1/Cip1/Sdi1 and bax.
Kaneuchi M; Yamashita T; Shindoh M; Segawa K; Takahashi S; Furuta I; Fujimoto S; Fujinaga K
Mol Carcinog; 1999 Sep; 26(1):44-52. PubMed ID: 10487521
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of HIF-1- and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions.
Blagosklonny MV; Giannakakou P; Romanova LY; Ryan KM; Vousden KH; Fojo T
Carcinogenesis; 2001 Jun; 22(6):861-7. PubMed ID: 11375890
[TBL] [Abstract][Full Text] [Related]
16. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
[TBL] [Abstract][Full Text] [Related]
17. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
18. Modulation of wild-type p53 activity by mutant p53 R273H depends on the p53 responsive element (p53RE). A comparative study between the p53REs of the MDM2, WAFI/Cip1 and Bax genes in the lung cancer environment. WAFI/Cip1 = WAF1/Cip1.
Zacharatos PV; Gorgoulis VG; Kotsinas A; Manolis EN; Liloglou T; Rassidakis AN; Kanavaros P; Field JD; Halazonetis T; Kittas C
Anticancer Res; 1999; 19(1A):579-87. PubMed ID: 10226602
[TBL] [Abstract][Full Text] [Related]
19. Mutation of the p51/p63 gene is associated with blastic crisis in chronic myelogenous leukemia.
Yamaguchi H; Inokuchi K; Sakuma Y; Dan K
Leukemia; 2001 Nov; 15(11):1729-34. PubMed ID: 11681414
[TBL] [Abstract][Full Text] [Related]
20. Mutational analysis of p51A/TAp63gamma, a p53 homolog, in non-small cell lung cancer and breast cancer.
Sunahara M; Shishikura T; Takahashi M; Todo S; Yamamoto N; Kimura H; Kato S; Ishioka C; Ikawa S; Ikawa Y; Nakagawara A
Oncogene; 1999 Jun; 18(25):3761-5. PubMed ID: 10391684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
